(NYSE: LLY) Eli Lilly & Co's forecast annual revenue growth rate of 13.44% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.22%.
Eli Lilly & Co's revenue in 2025 is $59,419,800,000.On average, 31 Wall Street analysts forecast LLY's revenue for 2025 to be $59,713,274,243,391, with the lowest LLY revenue forecast at $56,065,983,708,885, and the highest LLY revenue forecast at $63,752,899,037,052. On average, 31 Wall Street analysts forecast LLY's revenue for 2026 to be $70,864,075,657,206, with the lowest LLY revenue forecast at $65,131,268,554,758, and the highest LLY revenue forecast at $78,727,777,747,932.
In 2027, LLY is forecast to generate $82,006,368,617,208 in revenue, with the lowest revenue forecast at $72,932,575,317,522 and the highest revenue forecast at $95,383,548,778,758.